Gossamer Bio (NASDAQ:GOSS – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Institutional & Insider Ownership
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Gossamer Bio has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gossamer Bio | 2 | 3 | 4 | 0 | 2.22 |
| Dianthus Therapeutics | 1 | 0 | 13 | 1 | 2.93 |
Gossamer Bio presently has a consensus price target of $256.00, suggesting a potential upside of 2,649.73%. Dianthus Therapeutics has a consensus price target of $129.83, suggesting a potential upside of 57.62%. Given Gossamer Bio’s higher possible upside, research analysts clearly believe Gossamer Bio is more favorable than Dianthus Therapeutics.
Valuation and Earnings
This table compares Gossamer Bio and Dianthus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gossamer Bio | $48.47 million | 1.17 | -$170.37 million | ($56.00) | -0.17 |
| Dianthus Therapeutics | $2.04 million | 2,212.68 | -$162.34 million | ($4.15) | -19.85 |
Dianthus Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Gossamer Bio and Dianthus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gossamer Bio | -235.00% | N/A | -112.04% |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
Summary
Gossamer Bio beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
